- The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea . The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a U.S. appeals court in July. “Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
RT : Jazz Pharma's sleep disorder treatment gets FDA nod
The same drug to cure both OSA (Breathing) and Narcolepsy (Braincells) ? Think this story has to be looked at again. It also refers to Xyrem users as being ‘invalid’ ‘Invalid’ with regards to what exactly?
Wait what - same drug solriamfetol will work for OSA and Narcolepsy. This doesn’t sound right; these are very different sleep disorders.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »